Early detection of the risk of cognitive disorders

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

BACKGROUND: Cognitive disorders are a relevant problem in an aging population. Research shows a wide range of data on the prevalence of cognitive disorders in the general population. Thus, more studies on the prevalence of cognitive disorders and assessment of the risks of their development are necessary, which will determine the burden on the regional healthcare system.

AIM: To examine the prevalence of cognitive impairment in an outpatient multidisciplinary clinic setting and determine the risk ratios for cognitive deficits in different age groups.

MATERIALS AND METHODS: The Montreal Cognitive Assessment Scale was used in the screening of people aged 45–90 years.

RESULTS: Cognitive dysfunction was noted in 20.0% of patients in the group aged 45–59 years, 33.1% in the group aged 60–74 years, and 79.6% in the group aged 75–90 years. The average results on the assessment of cognitive functions of persons aged 45–59 (27.1±0.3) and 60–74 (26.2±0.2) years corresponded to the norm, and the value in persons aged 75–90 (23.6±0.3) years was below the norm. In groups aged 60–74 and 75–90 years, the prevalence of cognitive dysfunction was comparable between men and women. Cognitive impairments in men aged 45–59 years were recorded 2.5 times more often than that in women. The risk of cognitive disorders in the second group (aged 60–74 years) relative to that in the first group (aged 45–59 years) is insignificant (relative risk [RR], 1.21). In the third group (aged 75–90 years), the probability of cognitive disorders is significantly higher than that in the second group (RR=2.40) and nearly five times higher than that in the first group (RR=4.86).

CONCLUSION: Sex- and age-stratified screening indicators for assessing cognitive functions and the RRs of developing cognitive disorders in older age groups make it possible to plan for diagnostic, therapeutic, and preventive measures in mental health.

作者简介

Irina Mashkova

-

Email: mashkovairina2018@gmail.com
ORCID iD: 0000-0002-4342-671X

MD, cand. sci. (med.)

俄罗斯联邦, 20/1 Delegatskaja street, 127473 Моscow

Elena Dmitrieva

Smolensk State Medical University

Email: vernulas@mail.ru
ORCID iD: 0000-0003-1551-6563

senior lecturer

俄罗斯联邦, Smolensk

Anna Krikova

Smolensk State Medical University

Email: anna.krikova@mail.ru
ORCID iD: 0000-0002-5288-0447

MD, dr. sci. (pharm.), associate professor

俄罗斯联邦, Smolensk

Galina Aleschkina

A.I. Yevdokimov Moscow State University of Medicine and Dentistry

Email: aleshkina-ga@yandex.ru
ORCID iD: 0000-0001-7028-8669
SPIN 代码: 7477-8598

MD, dr. sci. (med.), associate professor

俄罗斯联邦, 20 Delegatskaya str., 127473, Moscow

Leonid Bardenshteyn

A.I. Yevdokimov Moscow State University of Medicine and Dentistry

编辑信件的主要联系方式.
Email: barden@mail.ru
ORCID iD: 0000-0002-1171-5517
SPIN 代码: 9289-9177

MD, dr. sci. (med.), professor

俄罗斯联邦, 20/1 Delegatskaja street, 127473 Моscow

参考

  1. Prince M, Guerchet M, Prina M. The epidemiology and impact of dementia — current state and future trends. WHO thematic briefing. 2015.
  2. Mikhaylova NM, Sokolova ON. Dementia in old age: from diagnosis to fatal outcome. V.M. Bekhterev Review of Psychiatry and Medical Psychology. 2020;(3):64–72. (In Russ). doi: 10.31363/2313-7053-2020-3-64-72
  3. Petersen RS, Smith GE, Waring SC, et al. Aging, memory and mild cognitive impairment. Int Psychogeriatr. 1997;9 suppl. 1:65–69. doi: 10.1017/s1041610297004717
  4. Peterson RS, Touchon J. Consensus in mild cognitive impairment. Research and practice in Alzheimers disease: EADS-ADCS. Res Pract Alzheimers Dis. 2005;10:38–46.
  5. Zakharov VV. Diagnosis and treatment of moderate cognitive impairment. Neurology, Neuropsychiatry, Psychosomatics. 2009;(2):14–18. (In Russ).
  6. Bogolepova A, Vasenina EE, Gomzyakova NA, et al. Clinical guidelines for cognitive disorders in elderly and older patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(10-3): 6–137. (In Russ). doi: 10.17116/jnevro20211211036
  7. Lyubov EB, Enaliev IR, Kryuchenkova TP. Clinical-epidemiological, pharmacoepidemiological and economic aspects of senile dementia. Social’naja i klinicheskaja psihiatrija. 2010;20(2):33–38. (In Russ).
  8. Cao Q, Tan CC, Xu W, et al. The prevalence of dementia: a systematic review and meta-analysis. J Alzheimers Dis. 2020; 73(3):1157–1166. doi: 10.3233/jad-191092
  9. Prince M, Bryce R, Albanese E, et al. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9(1):63–75.e2. doi: 10.1016/j.jalz.2012.11.007
  10. Prencipe M, Casini AR, Ferretti C, et al. Prevalence of dementia in an elderly rural population: effects of age, sex, and education. J Neurol Neurosurg Psychiatry. 1996;60(6):628–633. doi: 10.1136/jnnp.60.6.628
  11. Lucca U, Tettamanti M, Logroscino G, et al. Prevalence of dementia in the oldest old: The Monzino 80-plus population based study. Alzheimers Dement. 2015;11(3):258–270.e3. doi: 10.1016/j.jalz.2014.05.1750
  12. de Pedro-Cuesta J, Virués-Ortega J, Vega S, et al. Prevalence of dementia and major dementia subtypes in Spanish populations: a reanalysis of dementia prevalence surveys, 1990–2008. BMC Neurol. 2009;9:55. doi: 10.1186/1471-2377-9-55
  13. Vasenina EE, Levin OS, Sonin AG. Modern trends in epidemiology of dementia and management of patients with cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2017; 117(6-2):87–95. (In Russ). doi: 10.17116/jnevro20171176287-95
  14. Bogolepova AN. A contemporary view of the possibilities of preventing dementia. Medical Council. 2019;(18):52–58. (In Russ). doi: 10.21518/2079-701X-2019-18-52-58
  15. World Health Organization. Dementia: a public health priority. 2012. (In Russ).
  16. Puzin SN, Krivoruchko YuD. Medical and social aspects of the development of palliative care for patients with dementia. Russian Journal of Psychiatry. 2017;(4):13–22. (In Russ).
  17. Zakharov VV. All-Russia epidemiological and therapeutic investigation concerning cognitive impairment in the elderly (“Prometheus”). The Neurological Journal. 2006;11(2):27–32. (In Russ).
  18. Tsoi KK, Chan JY, Hirai HW, et al. Cognitive tests to detect dementia: a systematic review and meta-analysis. JAMA Intern Med. 2015;175(9):1450–1458. doi: 10.1001/jamainternmed.2015.2152
  19. Davis DH, Creavin ST, Yip JL, et al. Montreal Cognitive Assessment for the diagnosis of Alzheimer’s disease and other dementias. Cochrane Database Syst Rev. 2015;2015(10):CD010775. doi: 10.1002/14651858.CD010775.pub2
  20. Gantman MV. Identification of a dementia on outpatient appointment of elderly. Сovremennaja terapija v psihiatrii i nevrologii. 2016;(3):4–8. (In Russ).
  21. Kim H, Yu KH, Lee BC, et al. Validity of the Montreal Cognitive Assessment (MoCA) index scores: a comparison with the cognitive domain scores of the Seoul Neuropsychological Screening Battery (SNSB). Dement Neurocogn Disord. 2021;20(3):28–37. doi: 10.12779/dnd.2021.20.3.28
  22. Dautzenberg G, Lijmer J, Beekman A. Diagnostic accuracy of the Montreal Cognitive Assessment (MoCA) for cognitive screening in old age psychiatry: Determining cutoff scores in clinical practice. Avoiding spectrum bias caused by healthy controls. Int J Geriatr Psychiatry. 2020;35(3):261–269. doi: 10.1002/gps.5227
  23. Gaete M, Jorquera S, Bello-Lepe S, et al. Standardised results of the Montreal Cognitive Assessment (MoCA) for neurocognitive screening in a Chilean population. Neurologia (Engl Ed). 2022; S2173–S5808. doi: 10.1016/j.nrleng.2020.08.021
  24. Gutorova DA, Vasenina EE, Levin OS. Screening of cognitive impairment in the old and old-old population with the 3-CT scale. S.S. Korsakov Journal of Neurology and Psychiatry. 2016; 116(6-2):35–40. (In Russ). doi: 10.17116/jnevro20161166235-40
  25. Antonenko LM, Parfyonov VA. Cognitive and emotional disorders in middle age: diagnosis and treatment. Medical Council. 2015;(10):22–27. (In Russ).
  26. Bardenshtejn LM, Aleshkina GA. Ostrye i prehodjashhie psihoticheskie rasstrojstva: monografija. Moscow: ID «Medpraktika-M; 2017. (In Russ).
  27. Andrianova ED, Damulin IV, Sivolap JuP. Cognitive dysfunctions during alcoholism. Narkologija. 2013;12(6):79–85. (In Russ).
  28. Mashkova IY, Osipova NN, Aleshkina GA, et al. Comorbidity of dysthymia and addictive disorders. Psihicheskoe zdorov’e. 2022;17(12):81–91. (In Russ). doi: 10.25557/2074-014X.2022.12.81-91
  29. Sheremetyeva II, Plotnikov AV, Dokenova SV. Psychogenic disorders in persons with substance dependence syndrome due to an unfavorable epidemiological situation due to the spread of a new coronavirus infection. Sibirskij vestnik psihiatrii i narkologii. 2021;(4):71–78. (In Russ). doi: 10.26617/1810-3111-2021-4(113)-71-78
  30. Sheremetyeva II, Plotnikov AV, Dokenova SV, Moldagaliev TM. Impact of the novel coronavirus pandemic on the mental state of people with drug dependence syndrome. Bulletin of Medical Science. 2022;(1):83–87. (In Russ). doi: 10.31684/25418475_2022_1_83

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Histogram of the distribution of cognitive assessment scores in different age groups.

下载 (399KB)
索引源数据
3. Fig. 2. Chart comparing the mean scores on the cognitive assessment results of different age groups.

下载 (374KB)
索引源数据
4. Fig. 3. Individuals with cognitive impairment and relative risks of developing cognitive dysfunction in different age groups.

下载 (382KB)
索引源数据

版权所有 © Eco-Vector, 2023

Creative Commons License
此作品已接受知识共享署名-非商业性使用-禁止演绎 4.0国际许可协议的许可。
 


##common.cookie##